Allergan Inc. (AGN)

AGN (NYSE:Drugs)
$133.92
pos +0.00
+0.00%
Today's Range: 129.20 - 134.41 | AGN Avg Daily Volume: 2,946,100
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 20.56%
Open: $0.00
Previous Close: $131.46
52 Week Range: $81.33 - $134.41
Oustanding Shares: 298,467,649
Market Cap: 40,056,675,137
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 9 10 11
Moderate Buy 0 0 0 0
Hold 7 7 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.82 1.88 1.89 1.84
Latest Dividend: 0.05
Latest Dividend Yield: 0.15%
Dividend Ex-Date: 02/26/14
Price Earnings Ratio: 31.24
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
31.24 41.30 29.08
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.46% 18.53% 73.92%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
EBITDA 2.07B
Revenue 6.30B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.12 $1.35 $5.45 $6.17
Number of Analysts 12 12 15 14
High Estimate $1.15 $1.41 $5.50 $6.30
Low Estimate $1.09 $1.24 $5.38 $5.78
Prior Year $0.98 $1.22 $4.77 $5.45
Growth Rate (Year over Year) 14.03% 10.38% 14.24% 13.22%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 17, 2014 | 1:12 PM EDT

Some unexpected stocks and sectors have climbed the market's wall of worry.

bullishAllergan estimates, target raised at Credit Suisse

Feb 11, 2014 | 7:59 AM EST

Shares of AGN now seen reaching $140, according to Credit Suisse. Estimates also increased, as the company has multiple growth drivers. Outperform rating. 

By

Jim Cramer

 | Jan 14, 2014 | 3:50 PM EST

Believe in CEOs with a history of winning seasons.

bullishAllergan upgraded at Wells

Dec 24, 2013 | 7:23 AM EST

AGN was upgraded from Market Perform to Outperform, Wells Fargo said. New patents will likely protect Restasis. 

bullishAllergan lifts price target at UBS

Dec 20, 2013 | 8:05 AM EST

AGN raised its numbers, UBS said. Driven by new patents for Restasis. $116 price target and Buy rating. 

bullishAllergan estimates, target raised at Credit Suisse

Dec 12, 2013 | 7:53 AM EST

Shares of AGN now seen reaching $112, according to Credit Suisse. Estimates also increased, as management is turning the business around. Outperform rating. 

By

John Dorfman

 | Jul 12, 2013 | 10:30 AM EDT

Newmont Mining is attractive on several valuation measures

bearishAllergan target reduced at Lazard

Jul 11, 2013 | 7:41 AM EDT

Shares of AGN now seen reaching $100, according to Lazard Capital Markets Restasis could face increased competition from generics. Buy rating.

bearishAllergan downgraded at Wells

Jun 25, 2013 | 8:04 AM EDT

AGN was downgraded from Outperform to Market Perform, Wells Fargo said. Restasis will likely soon face generic competition.

bearishAllergan downgraded at Leerink Swann

Jun 24, 2013 | 8:00 AM EDT

AGN's future earnings estimates have been lowered as concern mounts over generic production of the firm's second largest drug, said Leerink Swann. New Market Perform rating, price target $102.

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.